Daito Pharmaceutical Co., Ltd. – FDA 483, Nov 6, 2017
Daito Pharmaceutical Co., Ltd. in Toyama-City, Japan, a manufacturer of finished dosage drugs and APIs, was cited for significant deficiencies in laboratory controls, data integrity, record-keeping, and quality unit oversight. The inspection revealed issues including unreported trial analyses, inadequate supervisory review of electronic data, non-contemporaneous record completion, and insufficient control over GMP documents and change control procedures. These observations indicate a systemic breakdown in the firm's quality management system.
- Person
ID · 3076416f-4c48-4816-94a9-e6132ac8bd55
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.